Skip to content

Researchers use A3 adenosine receptors to activate ‘off signals’ for chronic pain.

In a new study from Saint Louis University, researchers discovered that drugs targeting the A3 adenosine receptor can turn off pain signals in the spinal cord to provide relief from chronic pain.  Pain is the most common reason that people seek medical attention, but the available treatments, most commonly non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, are not always successful at relieving pain in patients with chronic pain state the team. For this reason the researchers decided to investigate a new target for treating chronic pain; the A3 adenosine receptor or A3AR.

In previous studies the lab has demonstrated that two drugs which target the A3AR, IB-MECA and MRS5698, were effective in treating several models of chronic pain, including painful chemotherapy-induced neuropathy, metastatic cancer pain, and nerve injury. More recently, the group sought to uncover the mechanism of A3AR pain relief.  Chronic pain can result from the loss of regulatory mechanisms in the nervous system pathway that transmits pain, explain the team.  Adenosine acts as a regulatory signaling molecule in other areas of the nervous system, so the team hypothesized that A3AR might also play a role in regulating pain signals during pain processing.

Indeed, the team found that A3AR drugs not only relieved pain, but did so by activating an inhibitory transmitter system known as the gamma amino-butyric acid (GABA) system. In areas of the spinal cord and brain dedicated to pain processing, A3AR activation promoted GABA signaling by preventing the breakdown and removal of GABA from neuronal synapses.  The team explain that in chronic pain, GABA signaling is often lost or diminished.  However, their A3AR drugs were able to restore GABA signaling in areas that process pain and turn off the signals that maintain the pain state.

With the team’s A3AR drugs demonstrating good safety profiles in clinical trials as anti-inflammatory and anti-cancer agents they are enthusiastic about the potential of these new drugs to treat chronic pain in patients.

The lab will continue to investigate the intricate mechanisms underlying A3AR pain relief with the hope of providing better palliative care to individuals suffering from unnecessary chronic pain.

Source:  Saint Louis University School of Medicine

 

SLU researchers show that A3 adenosine receptor can activate 'off signals' for pain

 

Healthinnovations View All

Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.

Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.

Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.

Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.

Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.

An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.

One thought on “Researchers use A3 adenosine receptors to activate ‘off signals’ for chronic pain. Leave a comment

Leave a Reply

Translate »